Placebo News and Research

RSS

Tea helps promote weight loss and improve bone health

Decades worth of research shows that tea-the second most consumed beverage in the world-may help prevent chronic illnesses, including heart disease, certain types of cancer and type 2 diabetes. New research shows tea has been found to help promote weight loss and maintain a healthy weight, improve bone health and activate areas of the brain that bolster attention, problem solving and mood.

7 Nov 2013

Sound Pharmaceuticals completes enrollment for SPI-1005 Phase 2 clinical trial

Sound Pharmaceuticals has successfully completed enrollment of its Phase 2 clinical trial with SPI-1005 at the University of Florida. This study enrolled 80 healthy subjects with normal or slight hearing loss and exposed the volunteer to calibrated music using an iPod and insert earphones.

5 Nov 2013

Trophos completes efficacy study of olesoxime in patients with Spinal Muscular Atrophy

Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, has completed its efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy.

5 Nov 2013

Genkyotex announces initiation of GKT137831 Phase II study in patients with diabetic nephropathy

Genkyotex, the leading developer of selective NOX enzyme inhibitors, announced today the initiation of a multinational Phase II clinical study of GKT137831 in patients with diabetic nephropathy.

5 Nov 2013

Magnesium deficiency may play important role in cognitive impairment

November is National Alzheimer's Awareness Month and the serious issues of cognitive health will be in the spotlight in the coming weeks. The medical community agrees that cognitive impairment, ranging from mild to severe, is almost epidemic in the U.S. as the Baby Boomer generation is aging and living longer. Scientists believe one reason is that the human brain begins shrinking after age 25. Structural changes and loss of brain synapses lead to rapid decline in cognitive health.

5 Nov 2013

Generic drug gabapentin appears to be safe, effective in treating alcohol dependence

The generic drug gabapentin, which is already widely prescribed for epilepsy and some kinds of pain, appears to be safe and effective in the treatment of alcohol dependence. The finding comes from a 150-patient randomized, placebo-controlled, double blind clinical trial conducted by scientists at The Scripps Research Institute.

4 Nov 2013

BioLineRx obtains regulatory approval to initiate BL-7010 Phase 1/2 trial for celiac disease

BioLineRx, a biopharmaceutical development company, announced today that it has received regulatory approval from the Finnish National Supervisory Authority for Welfare and Health (Valvira) to commence a Phase 1/2 safety trial for BL-7010, for the treatment of celiac disease.

4 Nov 2013

Toxicity limits benefits of bevacizumab–erlotinib NSCLC maintenance therapy

Two targeted anticancer drugs used together after first-line chemotherapy for advanced stage non-small-cell lung cancer improve progression-free survival, the results of a large, prospective study show.

31 Oct 2013

Array BioPharma reports net loss of $0.13 per share for first quarter of fiscal 2014

Array BioPharma Inc. today reported results for the first quarter of its fiscal year ending June 30, 2014.

31 Oct 2013

Kamada announces new data from Glassia Phase I/II study in pediatric patients with type 1 diabetes

Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, today reported preliminary data from the Company's ongoing extension study of a Phase I/II clinical trial with its lead product Glassia® to treat pediatric patients with a recently diagnosed type 1 diabetes (T1D).

31 Oct 2013

IQWiG completes first health economic evaluation

The German Institute for Quality and Efficiency in Health Care has completed its first health economic evaluation. The report on antidepressants published on 30 October 2013 shows that the "efficiency frontier method" works and can provide very helpful results.

31 Oct 2013

CytoDyn submits protocol to FDA for Phase IIb clinical trial of PRO 140

CytoDyn Inc. ("CytoDyn") (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that CytoDyn Chief Medical Officer David Feigal, M.D., has submitted a revised protocol to the U.S. Food and Drug Administration relating to an upcoming Phase IIb clinical trial of PRO 140, CytoDyn's leading product under development as a treatment for Human Immunodeficiency Virus (HIV) infection.

31 Oct 2013

Once-daily prescription medicine for COPD now available throughout the U.S.

GlaxoSmithKline plc and Theravance, Inc. today announced that BREO ELLIPTA, a once-daily prescription medicine for chronic obstructive pulmonary disease, is now available to pharmacies throughout the U.S.

30 Oct 2013

Acacia Pharma begins APD403 Phase II study to prevent chemotherapy-induced nausea & vomiting

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces the initiation of a Phase II study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV).

30 Oct 2013

Researchers identify new drug for treating irritable bowel syndrome with constipation

An international team led by University of Adelaide researchers has identified the mechanism of pain relief of a new drug for treating Irritable Bowel Syndrome with Constipation (IBS-C), based on nonclinical studies, and quantified its effectiveness in pain relief in human trials.

30 Oct 2013

Study investigates link between sedentary behavior and recurrence of colorectal adenomas

Men who spend the most time engaged in sedentary behaviors are at greatest risk for recurrence of colorectal adenomas, benign tumors that are known precursors of colorectal cancers, according to results presented here at the 12th Annual AACR International Conference on Frontiers in Cancer Prevention Research, held Oct. 27-30.

29 Oct 2013

Pharmalink's Busulipo receives FDA orphan drug designation

Pharmalink AB, a specialty pharma company focused on orphan and niche products, today announces its product Busulipo, a best-in-class conditioning agent for use in cancer patients prior to hematopoietic stem cell transplantation (HSCT; also known as bone marrow transplantation), has received orphan drug designation from the US Food and Drug Administration.

29 Oct 2013

Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

New findings from two integrated Phase 3 Janssen Research & Development, LLC (Janssen)-sponsored studies showed treatment with STELARA- (ustekinumab) resulted in significantly greater inhibition of structural damage in patients with active psoriatic arthritis compared with placebo.

29 Oct 2013

Regular cannabis users have increased levels of impulsive behaviour, reveals research

New cocaine and cannabis research reveals that regular cannabis users have increased levels of impulsive behaviour. It had previously been argued that this increased impulsivity after cannabis administration was only experienced by occasional users, but that regular users were no longer affected in this way.

29 Oct 2013

Incyte announces results of Phase II clinical trial of oral JAK1 inhibitor in patients with RA

Incyte Corporation (Nasdaq: INCY) announced results from a 12-week, placebo-controlled, dose-escalationin involving 60 patients with active rheumatoid arthritis for its proprietary oral JAK1 inhibitor.

29 Oct 2013

Placebo News and Research

Tea helps promote weight loss and improve bone health

Sound Pharmaceuticals completes enrollment for SPI-1005 Phase 2 clinical trial

Trophos completes efficacy study of olesoxime in patients with Spinal Muscular Atrophy

Genkyotex announces initiation of GKT137831 Phase II study in patients with diabetic nephropathy

Magnesium deficiency may play important role in cognitive impairment

Generic drug gabapentin appears to be safe, effective in treating alcohol dependence

BioLineRx obtains regulatory approval to initiate BL-7010 Phase 1/2 trial for celiac disease

Toxicity limits benefits of bevacizumab–erlotinib NSCLC maintenance therapy

Array BioPharma reports net loss of $0.13 per share for first quarter of fiscal 2014

Kamada announces new data from Glassia Phase I/II study in pediatric patients with type 1 diabetes

IQWiG completes first health economic evaluation

CytoDyn submits protocol to FDA for Phase IIb clinical trial of PRO 140

Once-daily prescription medicine for COPD now available throughout the U.S.

Acacia Pharma begins APD403 Phase II study to prevent chemotherapy-induced nausea & vomiting

Researchers identify new drug for treating irritable bowel syndrome with constipation

Study investigates link between sedentary behavior and recurrence of colorectal adenomas

Pharmalink's Busulipo receives FDA orphan drug designation

Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

Regular cannabis users have increased levels of impulsive behaviour, reveals research

Incyte announces results of Phase II clinical trial of oral JAK1 inhibitor in patients with RA

Industry Focus eBook - Cell biology (5th edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News